NEW YORK (GenomeWeb News) – PerkinElmer this week announced the establishment of direct operations in Israel, headquartered near Tel Aviv. Through its new Israel base, PerkinElmer will commercialize and support its life sciences and technologies, analytical sciences, and laboratory services business offerings.

The company's board separately last week declared a quarterly dividend of $.07 per share, payable on Nov. 8 to shareholders of record at the close of business on Oct. 18.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.